CSDX (CS Diagnostics) Cash Flow for Lease Financing: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CS Diagnostics Cash Flow for Lease Financing?

CS Diagnostics CSDX +163.64% Cash Flow for Lease Financing is $0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

CS Diagnostics's Cash Flow for Lease Financing for the three months ended in Dec. 2025 was $0.00 Mil. CS Diagnostics's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Sep. 2025 ), CS Diagnostics's Cash Flow for Lease Financing remained the same in Dec. 2025 ($0.00 Mil).

CS Diagnostics Cash Flow for Lease Financing Historical Data

* Premium members only.

The historical data trend for CS Diagnostics's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CS Diagnostics Cash Flow for Lease Financing Chart

CS Diagnostics Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec24 Dec25
Cash Flow for Lease Financing
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

CS Diagnostics Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CS Diagnostics Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Lease Financing of $0.00 Mil mean?
CS Diagnostics (CSDX) has a Cash Flow for Lease Financing of $0.00 Mil as of Dec. 2025. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on CS Diagnostics and its competitors.
Is CS Diagnostics' Cash Flow for Lease Financing too high?
CS Diagnostics' current Cash Flow for Lease Financing is $0.00 Mil.
How does CS Diagnostics' Cash Flow for Lease Financing compare to ADMT and POAS?
CS Diagnostics' Cash Flow for Lease Financing of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Lease Financing for a Medical Devices & Instruments company?
A good Cash Flow for Lease Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow for Lease Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Lease Financing mean?
A high Cash Flow for Lease Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on CS Diagnostics and its competitors. CS Diagnostics's current Cash Flow for Lease Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CS Diagnostics stock overvalued right now?
CS Diagnostics (CSDX) has a current Cash Flow for Lease Financing of $0.00 Mil. The current Cash Flow for Lease Financing is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Lease Financing calculated?
Cash Flow for Lease Financing is calculated from a company's financial statements. For CS Diagnostics (CSDX), the current Cash Flow for Lease Financing is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CS Diagnostics Business Description

Address 1603 Capitol Avenue, Suite 413, Cheyenne, WY, USA, 82001
CS Diagnostics Corp is a United States based Corporation, its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit.